AXN Aoxing Pharmaceutical Company New (delisted)

Common Stock, $.001 par value

(Title of each class of securities covered by this Form)

    ____________________________________________________________________________________

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)	☒
Rule 12g-4(a)(2)	☐
Rule 12h-3(b)(1)(i)	☐
Rule 12h-3(b)(1)(ii)	☐
Rule 15d-6	☐
Rule 15d-22(b)	☐

 

Approximate number of holders of record as of the certification or notice date: 287

Pursuant to the requirements of the Securities Exchange Act of 1934, Aoxing Pharmaceutical Company, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: October 16, 2017

By: /s/ Zhenjiang Yue Zhenjiang Yue, Chief Executive Officer

     

Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934.  The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed.  It may be signed by an officer of the registrant, by counsel or by any other duly authorized person.  The name and title of the person signing the form shall be typed or printed under the signature.

 

 

 

---